A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-negative Metastatic Breast Cancer
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Trastuzumab-deruxtecan (Primary) ; Abemaciclib; Anastrozole; Atezolizumab; Carboplatin; Docetaxel; Epirubicin; Eribulin; Exemestane; Fulvestrant; Gemcitabine; Letrozole; Paclitaxel; Pertuzumab; Ribociclib; Tamoxifen; Vinorelbine
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms DISCORDANT
- 03 Oct 2024 Trial phase changed from 4 to 3. Drug Pembrolizumab and Trastuzumab removed and Trastuzumab deruxtecan added in the study protocol. Planned number of patients also increased.
- 03 Oct 2024 Planned number of patients changed from 250 to 504.
- 30 Sep 2024 New trial record